Disease · MONDO_0100339
Trials49
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
1 to 20 of 49
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00905268 | A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients | Phase 3 | 232 | 2016-06-27 | Friedreich's Ataxia | IDEBENONE | Its record names the disease | ClinicalTrials.gov |
| NCT00993967 | Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension) | Phase 3 | 200 | 2018-03-05 | Freidreich's Ataxia | IDEBENONE | Its record names the disease | ClinicalTrials.gov |
| NCT02255435 | A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia | Phase 2 | 172 | 2022-11-29 | Friedreich Ataxia | OMAVELOXOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT02415127 | Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia | Phase 3 | 92 | 2017-12-08 | Friedreich's Ataxia | INTERFERON GAMMA-1B | Its record names the disease | ClinicalTrials.gov |
| NCT02593773 | Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study | Phase 3 | 86 | 2018-05-18 | Friedreich's Ataxia | INTERFERON GAMMA-1B | Its record names the disease | ClinicalTrials.gov |
| NCT00537680 | Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia | Phase 3 | 70 | 2011-12-29 | Friedreich's Ataxia | IDEBENONE | Its record names the disease | ClinicalTrials.gov |
| NCT00697073 | Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients | Phase 3 | 68 | 2011-08-04 | Friedreich's Ataxia | IDEBENONE | Its record names the disease | ClinicalTrials.gov |
| NCT03214588 | Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia | Phase 2 | 67 | 2019-12-19 | Friedreich Ataxia | LUVADAXISTAT | Its record names the disease | ClinicalTrials.gov |
| NCT02797080 | Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia | Phase 3 | 38 | 2018-05-01 | Friedreich's Ataxia | INTERFERON GAMMA-1B | Its record names the disease | ClinicalTrials.gov |
| NCT01303406 | Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI) | Phase 3 | 29 | 2016-03-09 | Friedreich's Ataxia | IDEBENONE | Its record names the disease | ClinicalTrials.gov |
| NCT00824512 | Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia | Phase 2 | 22 | 2013-05-21 | Friedreich Ataxia | GINKGO | Its record names the disease | ClinicalTrials.gov |
| NCT05168774 | FRDA Investigator Initiated Study (IIS) With Elamipretide | Phase 1/2 | 20 | 2025-12-12 | Friedreich Ataxia | ELAMIPRETIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01965327 | Interferon Gamma-1b in Friedreich Ataxia (FRDA) | Phase 2 | 12 | 2015-04-30 | Friedreich Ataxia | INTERFERON GAMMA-1B | Its record names the disease | ClinicalTrials.gov |
| NCT02660112 | (+) Epicatechin to Treat Friedreich's Ataxia | Phase 2 | 10 | 2019-12-05 | Friedreich's Ataxia | (+)-EPICATECHIN, (-)-EPICATECHIN | Its record names the disease | ClinicalTrials.gov |
| NCT06623890 | A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors | 300 | Friedreich Ataxia | OMAVELOXOLONE | Its record names the disease | ClinicalTrials.gov | ||
| NCT06953583 | A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia | Phase 3 | 255 | Friedreich Ataxia | OMAVELOXOLONE | Its record names the disease | ClinicalTrials.gov | |
| NCT04577352 | A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia | Phase 2/3 | 146 | Friedreich Ataxia | VATIQUINONE | Its record names the disease | ClinicalTrials.gov | |
| NCT05515536 | A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia | Phase 3 | 130 | Friedreich Ataxia | VATIQUINONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00015808 | Safety Study of Idebenone to Treat Friedreich's Ataxia | Phase 1 | 100 | Friedreich Ataxia | IDEBENONE | Its record names the disease | ClinicalTrials.gov | |
| NCT06447025 | An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia | Phase 2 | 85 | Friedreich Ataxia | NOMLABOFUSP | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100339/trials